References
- 1. Wada H, Inagaki N, Itowi N, Yamatodani A. Histaminergic neuron system in the brain: distribution and possible functions. Brain Res Bull. 1991;27(3-4):367-70.
- 2. Wyngaarden JB, Seevers MH. The toxic effects of antihistaminic drugs. J Am Med Assoc. 1951;145(5):277-82.
- 3. Churchill JA, Gammon GD. The effect of antihistaminic drugs on convulsive seizures. J Am Med Assoc. 1949;141(1):18-21.
- 4. Gerald MC, Richter NA. Studies on the effects of histaminergic agents on seizure susceptibility in mice. Psychopharmacologia. 1976; 46(3):277-82.
- 5. Tuomisto L, Tacke U. Is histamine an anticonvulsive inhibitory transmitter? Neuropharmacology. 1986;25(8):955-8.
- 6. Scherkl R, Hashem A, Frey HH. Histamine in brain-its role in regulation of seizure susceptibility. Epilepsy Res. 1991;10(2-3):111-8.
- 7. Świąder M, Kalisz A, Porebiak J, Kleinrok Z, Czuczwar SJ. Influence of antazoline on the anticonvulsant activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Pol J Pharmacol. 1999;51(1):104.
- 8. Świąder M, Chwalczuk K, Wielosz M, Czuczwar SJ. Influence of chronic treatment with H1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs. Pol J Pharmacol. 2001;53(1):93-6.
- 9. Świąder MJ, Łuszczki JJ, Wielosz M, Czuczwar SJ. Effect of histamine receptor antagonists on aminophylline-induced seizures and lethality in mice. Pharmacol Rep. 2005;57(4):531-5.
- 10. Świąder MJ, Czuczwar SJ. Interaction of famotidine, an H2 histamine receptor antagonist, with conventional antiepileptic drugs in mice. Pharmacol Rep. 2014;66(3):485-91.
- 11. Oyewumi LK, Vollick D, Merskey H, Plumb C. Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci. 1994;19(2):145-50.
- 12. Yuan RY, Kao CR, Sheu JJ, Chen CH, Ho CS. Delirium following a switch from cimetidine to famotidine. Ann Pharmacother. 2001; 35(9):1045-8.